Key result
Icosapent ethyl reduces total hospitalizations by ~9% compared to placebo.
Why the study?
Does icosapent ethyl reduce total hospitalizations and days lost to hospitalization and death in statin-treated patients with elevated triglycerides and cardiovascular risk factors?
RCT (n=8,179)
Does icosapent ethyl reduce total hospitalizations and days lost to hospitalization and death in statin-treated patients with elevated triglycerides and cardiovascular risk factors?
Hazard Ratio: 0.91 (95% CI 0.84–0.98)
p-value: p=0.017
No takes yet. Share an insight, caveat, or question.
In a post hoc analysis of the REDUCE-IT trial, icosapent ethyl significantly reduced total hospitalizations and days lost to hospitalization and death compared to placebo.
Szarek et al. (2025) conducted an RCT in elevated triglycerides and known cardiovascular disease or diabetes (n=8,179). icosapent ethyl vs. placebo was evaluated on total hospitalizations (HR 0.91, 95% CI 0.84-0.98, p=0.017). Icosapent ethyl significantly reduced total hospitalizations compared to placebo (HR 0.91; 95% CI 0.84-0.98; P=0.017) over a median of 5.0 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: